Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer

Fig. 4

CDKL1 overexpression inhibits YBX1 accumulation at the PD-L1 promoter but does not affect YBX1 localization. (A) The expression of YBX1 in the cytoplasm and nucleus was assessed in A549 and H1299 cells overexpressing CDKL1. (B) The nuclear and cytoplasmic localization of YBX1 was detected by immunofluorescence staining, and statistical analysis was performed (n.s. indicates P > 0.05). Scale bar, 50 μm. (C) The gel electrophoresis results of H1299 cells transfected with SFB-CDKL1 are presented as representative images. The levels of YBX1 at the PD-L1 promoter were normalized to the concentration of input DNA (** P < 0.01, *** P < 0.001). (D) The gel electrophoresis results of A549 cells transfected with si-CDKL1 are shown as representative images. The levels of YBX1 at the PD-L1 promoter were normalized to the concentration of input DNA (** P < 0.01, *** P < 0.001)

Back to article page